Category Archives: Corporate

Although more expensive, study says teaching hospitals save more lives. My personal take.






Perhaps not evident to many patients, there are two kinds of hospitals–teaching and nonteaching–and an intense debate about which is better. Teaching hospitals, affiliated with medical schools, are the training grounds… Read more »

Idorsia leaps 45% in market debut; Actelion spinoff looks like sure bet with J&J backing to boot. How to invest.






Idorsia Ltd. (Allschwil CHE), the research-based spin-out from Actelion following the latter’s $30 billion acquisition by Johnson & Johnson (New Brunswick NJ), which has now been completed, started trading on… Read more »

Merck’s Keytruda aces another cancer trial as results dazzle researchers






The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

Tesaro says it’s for sale, but who can afford it






The News: Just ahead of the year’s biggest download of cancer data, the maker of a closely watched drug has put itself up for sale, according to The Wall Street… Read more »

What’s wrong with Novartis? Actually nothing.






The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Biogen spinoff Bioverativ buys Bristol-Myers’ iPierian spinout True North for $825 million; deal shows how to get several bites at the same assets






The News: Bioverativ Inc. (Waltham MA) announced that it entered into a definitive agreement to acquire True North Therapeutics Inc. (South San Francisco) for up to $825 million, including an… Read more »

Puma doubles on FDA panel’s nod for breast-cancer drug; but Swiss giant’s challenger lurks






The News: Puma Biotechnology Inc.’s (Los Angeles) experimental breast cancer drug reduces the risk of disease recurrence and should be approved, an advisory committee to the US Food and Drug… Read more »

Amgen’s osteoporosis med almost a home run in latest trial; fate now murky on heart safety






The News: Amgen Inc. (Thousand Oaks CA) and UCB SA (Brussels) no longer expect their experimental osteoporosis drug to win US approval this year after a higher rate of serious… Read more »

GlycoMimetics gets Breakthrough title; stock explodes but what’s next?






The News: GlycoMimetics Inc. (Rockville MD) soared Thursday (May 18, 2017), up 99% to $10.67. The unforeseen blastoff followed Tuesday (May 16, 2017) night’s announcement that the company’s clinical-stage acute… Read more »

Akebia surges on anemia drug deal; is a much bigger breakout looming?






The News: Akebia Therapeutics Inc. (Cambridge MA) leaped 18% Tuesday (May 16, 2017) sparked by news the fledgling dialysis treatment developer and Swiss backer Vifor Pharma Group Ltd. (Glattburg) agreed… Read more »